» Articles » PMID: 21471433

Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission

Abstract

High plasma HIV-1 RNA concentrations are associated with an increased risk of HIV-1 transmission. Although plasma and genital HIV-1 RNA concentrations are correlated, no study has evaluated the relationship between genital HIV-1 RNA and the risk of heterosexual HIV-1 transmission. In a prospective study of 2521 African HIV-1 serodiscordant couples, we assessed genital HIV-1 RNA quantity and HIV-1 transmission risk. HIV-1 transmission linkage was established within the partnership by viral sequence analysis. We tested endocervical samples from 1805 women, including 46 who transmitted HIV-1 to their partner, and semen samples from 716 men, including 32 who transmitted HIV-1 to their partner. There was a correlation between genital and plasma HIV-1 RNA concentrations: For endocervical swabs, Spearman's rank correlation coefficient ρ was 0.56, and for semen, ρ was 0.55. Each 1.0 log(10) increase in genital HIV-1 RNA was associated with a 2.20-fold (for endocervical swabs: 95% confidence interval, 1.60 to 3.04) and a 1.79-fold (for semen: 95% confidence interval, 1.30 to 2.47) increased risk of HIV-1 transmission. Genital HIV-1 RNA independently predicted HIV-1 transmission risk after adjusting for plasma HIV-1 quantity (hazard ratio, 1.67 for endocervical swabs and 1.68 for semen). Seven female-to-male and four male-to-female HIV-1 transmissions (incidence <1% per year) occurred from persons with undetectable genital HIV-1 RNA, but in all 11 cases, plasma HIV-1 RNA was detected. Thus, higher genital HIV-1 RNA concentrations are associated with greater risk of heterosexual HIV-1 transmission, and this effect was independent of plasma HIV-1 concentrations. These data suggest that HIV-1 RNA in genital secretions could be used as a marker of HIV-1 sexual transmission risk.

Citing Articles

Suppressed but still infectious.

Gianella S, Haubrich R, Morris S Future Virol. 2024; 8(11):1037-1040.

PMID: 39640894 PMC: 11619922. DOI: 10.2217/fvl.13.89.


Enhanced metabolic health and immune response with bictegravir/emtricitabine/TAF: Insights from a 96‑week retrospective study.

Spampinato S, Conti G, Marino A, Raimondo V, Celesia B, Pellicano G Biomed Rep. 2024; 21(6):179.

PMID: 39387001 PMC: 11462501. DOI: 10.3892/br.2024.1867.


Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates.

Vanshylla K, Tolboom J, Stephenson K, Feddes-de Boer K, Verwilligen A, Rosendahl Huber S NPJ Vaccines. 2024; 9(1):179.

PMID: 39349488 PMC: 11442979. DOI: 10.1038/s41541-024-00974-1.


Sexually transmitted infections and bacterial vaginosis among adolescent girls and young women in the early postpartum period: a cross-sectional study.

Govender V, Naidoo M, Moodley D BMC Infect Dis. 2024; 24(1):898.

PMID: 39223449 PMC: 11367844. DOI: 10.1186/s12879-024-09781-4.


Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F Int J Mol Sci. 2024; 25(3).

PMID: 38338977 PMC: 10855115. DOI: 10.3390/ijms25031704.


References
1.
Pilcher C, Joaki G, Hoffman I, Martinson F, Mapanje C, Stewart P . Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS. 2007; 21(13):1723-30. PMC: 2673564. DOI: 10.1097/QAD.0b013e3281532c82. View

2.
Lingappa J, Hughes J, Wang R, Baeten J, Celum C, Gray G . Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010; 5(9):e12598. PMC: 2938354. DOI: 10.1371/journal.pone.0012598. View

3.
Lingappa J, Kahle E, Mugo N, Mujugira A, Magaret A, Baeten J . Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One. 2009; 4(4):e5272. PMC: 2671170. DOI: 10.1371/journal.pone.0005272. View

4.
Kaul R, Pettengell C, Sheth P, Sunderji S, Biringer A, MacDonald K . The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol. 2007; 77(1):32-40. DOI: 10.1016/j.jri.2007.02.002. View

5.
Zuckerman R, Lucchetti A, Whittington W, Sanchez J, Coombs R, Zuniga R . Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007; 196(10):1500-8. DOI: 10.1086/522523. View